Three patients with end-stage renal failure complicating systemic amyloidosis have been treated with continuous ambulatory peritoneal dialysis for periods of 10, 14 and 18 months respectively. In each case satisfactory control of uraemia and fluid balance has been achieved.
Introduction
Systemic amyloidosis is an uncommon disease which is characterized by the widespread deposition of homogeneous protein fibrils. Two types predominate: AA amyloid (derived from serum amyloid protein A) which occurs in reactive systemic (secondary) amyloidosis, and AL amyloid (derived from light chains of the immunoglobulin molecule) which occurs in primary and myeloma-associated amyloidosis. Renal involvement is common in both types (Browning et al. 1983 ) and usually manifests itself as the nephrotic syndrome with a variable degree of renal impairment which may progress to end-stage renal disease. Haemodialysis (Gurland et al. 1973 ) and renal transplantation (Cohen et al. 1971 ) have been used for over 10 years in the treatment of end-stage renal failure complicating systemic amyloidosis, and their roles are now established. The place of chronic peritoneal dialysis has still to be assessed. We report here on 3 patients with end-stage renal disease and systemic amyloidosis who have been treated with continuous ambulatory peritoneal dialysis (CAPD) for 10, 14 and 18 months respectively.
Case reports
Renal biopsy specimens were stained for amyloid with Sirius Red and Cresyl Violet and the potassium permanganate pretreatment technique of Wright et al. (1977) . The distribution and staining characteristics of amyloid in biopsy material enabled the cases to be divided into AA and AL amyloidosis.
Case 1: In December 1979 a 64-year-old man was investigated for ankle swelling and proteinuria. Previously diagnosed hypertension was controlled by methyldopa. On examination there was marked ankle oedema and his spine was rigid and immobile. Blood urea was 8.2 mmol/l, serum creatinine 132 Mmol/l, albumin 23 g/l and urinary protein excretion 7.9 g/24 hours. Radiological examination showed ankylosing spondylitis. Renal biopsy demonstrated glomerular and interstitial amyloid of AA type and nephrosclerosis. He was treated with diuretics and a 12-month course of D-penicillamine and chlorambucil. Despite good control of his blood pressure with a betablocker, there was progressive deterioration of his renal function. In November 1981 he was admitted for commencement on CAPD with a serum creatinine of 1518 jimol/l, blood urea 39.7 mmol/l, and haemoglobin 8.5 g/dl. He experienced no complications on starting dialysis and was discharged on the home CAPD programme 2 weeks later on a regimen of 4 x 2 litre 'Accepted 12 October 1983 (D 1984 The Royal Society of Medicine 0141-0768/84/030189--04/$01.00/0 peritoneal dialysate exchanges per day. In March 1982 he was admitted for 4 days with an episode of peritonitis which was treated with 48 hours rapid cycling of dialysis fluid and 10 days intraperitoneal cefuroxime 250 mg/l of dialysate. Two further episodes of peritonitis were treated at home. In October 1982 he was admitted for 3 days for revision of his Tenckhoff catheter. He remains well and active, is free of oedema and has a normal blood pressure in spite of withdrawal of antihypertensive drugs. Blood urea has been well controlled. Less effective reduction of his serum creatinine may be explained by his large body mass (Table 1) .
Case 2: In May 1978 a 28-year-old woman developed the nephrotic syndrome. Creatinine clearance was 82 ml/minute, serum albumin 19 g/l, and urinary protein 7.2 g/24 hours. Renal biopsy showed moderate glomerular amyloid of AA type and she was treated with diuretics. A rectal biopsy in July, however, showed not only amyloid infiltration but also active Crohn's disease, for which she received sulphasalazine. In March 1979 D-penicillamine and chlorambucil were added to her treatment regimen as the nephrotic syndrome had persisted. In January 1980 there was a rapid decline in her renal function, creatinine clearance falling to 16 ml/minute in the space of one month, and renal biopsy was repeated. This showed an increase in glomerular amyloid with, in addition, interstitial and vascular amyloid deposition. Dimethylsulphoxide 10 ml twice daily was started in place of penicillamine and chlorambucil. Her renal function, however, continued to deteriorate. In March 1982 she was admitted acutely uraemic with a serum creatinine of 1673 4umol/l, blood urea 34.3 mmol/l and haemoglobin 9.2 g/dl. Peritoneal dialysis was commenced at once and CAPD was started in April 1982. The initial regimen of 4 x 2 litre exchanges per day was reduced to 3 x 2 litre exchanges after 4 months. She has had one episode of peritonitis, which was treated at home with 10 days intraperitoneal cefotaxime 250 mg/l of dialysate, and she has been readmitted for revision of her Tenckhoff catheter. Her blood urea and serum creatinine have been well controlled (Table 1) . She remains active and awaits renal transplantation.
Case 3: A 65-year-old nurse presented in January 1982 with exercise dyspnoea and hypertension. On examination her blood pressure was 240/105, she had hypertensive retinopathy (grade III) and was fluid overloaded. Investigations showed blood urea 20 mmol/l, serum creatinine 484 imol/l and urinary protein excretion 9 g/24 hours. Renal biopsy showed extensive amyloid deposition of AL type. Plasma and urinary electrophoresis and bone marrow examination were normal. She was treated with diuretics, metoprolol and hydralazine. During follow-up, control of her fluid balance and hypertension were difficult and her renal function progressively declined. She was admitted to commence CAPD in August 1982 with blood urea 58.8 mmol/l, serum creatinine 1296 ,umol/l, haemoglobin 6.8 g/dl and severe fluid overload. There were no complications on starting dialysis and she was discharged 2 weeks later, without oedema, on the home CAPD programme on a regimen of 4 x 2 litre exchanges per day. Two episodes of peritonitis shortly after discharge were treated at home with 10 days intraperitoneal cefuroxime 250 mg/l of dialysate. A third peritoneal infection required hospital admission for 5 days. She is free of oedema and is normotensive without antihypertensive therapy. Blood urea and serum creatinine are shown in Table 1 .
Discussion
There is little evidence that drug treatment affects the progression of renal amyloidosis (Lancet 1980) , and end-stage renal failure is a common outcome (Browning et al. 1983 , Jones 1976 ). Dialysis and transplantation have markedly improved the prognosis of such patients. The results of maintenance haemodialysis in systemic amyloidosis, however, are not so good as in patients with nonsystemic diseases (Gurland et al. 1976) . A high incidence of death due to circulatory disorders has been reported (Jones 1976) , and caution should therefore be exercised in selecting for haemodialysis patients who have evidence of cardiac amyloid involvement. Results of renal transplantation in amyloidosis have also shown a reduced patient survival rate compared with other renal -transplant recipients (Jones 1976 , Kennedy & Castro 1977 . Amyloid infiltration of the allograft may occur (Kuhlback et al. 1979 , ASC/NIH 1975 . The limiting factor in graft function, however, is rejection rather than the recurrence of renal amyloid (Lancet 1980) . The role of peritoneal dialysis in the treatment of end-stage renal failure complicating systemic amyloidosis has yet to be evaluated. Stone et al. (1978) described the use of chronic intermittent peritoneal dialysis in a patient with amyloidosis, paraproteinaemia and factor X deficiency. We know of no other reports. Our three cases demonstrate that CAPD can provide a suitable means of long-term treatment in patients with end-stage renal amyloidosis of both AA and AL types. In all three cases a satisfactory quality of life has been maintained and control of uraemia has been achieved, suggesting adequate dialysis and ultrafiltration across a peritoneum potentially infiltrated by amyloid. In a total of 42 months of dialysis our patients have spent only 16 days in hospital since starting on the home dialysis programme. The incidence of peritonitis in these patients (one episode per 6 months) compares favourably with the incidence for all other patients on CAPD in our unit over the same period (one episode of peritonitis per 5.8 months).
Hypotension may complicate both amyloidosis (Kyle & Bayrd 1975) and CAPD (Marquez-Julio et al. 1980) . Low blood pressure has not been a problem in our patients, but two of the three have had antihypertensive therapy withdrawn and remain normotensive on CAPD alone. One of our patients has ankylosing spondylitis (Case 1). He has not experienced any increase in discomfort nor limitation of spinal movement resulting from the presence of peritoneal dialysis fluid. Another patient has Crohn's disease (Case 2). This has remained clinically inactive and has not increased her risk of developing peritonitis (one episode in 14 months on CAPD) nor interfered with her dialysis. CAPD has several advantages over haemodialysis in the management of end-stage renal disease. It is not associated with the circulatory stress of intermittent haemodialysis, and haemoglobin levels are better preserved on CAPD (Lamperi et al. 1981) (Table 1) . Both these factors may be important in the presence of amyloid cardiomyopathy and coronary artery disease. Furthermore, although the vascular access required for haemodialysis is not in itself a problem with vessels infiltrated with amyloid, spontaneous subcutaneous haemorrhage at the site of vascular access has been reported (Jones 1976) . The low cost and rapidity with which patients may be established on home dialysis with CAPD (Beardsworth & Goldsmith 1982) is also an important consideration given the relatively poor prognosis of some of these patients by virtue of non-renal organ involvement (Browning et al. 1983 ).
Finally, immunoglobulin light chains, the precursor proteins of the amyloid fibrils in AL amyloidosis, are dialysed across the peritoneum (Stone et al. 1978) . Removal of these proteins by CAPD may limit the progression of amyloid deposition in this condition.
In spite of our encouraging results, not all patients with end-stage renal amyloidosis will prove suitable for CAPD. Patients with underlying rheumatoid disease may have limited manual dexterity, making CAPD impractical without help from a relative. We suggest, however, that CAPD may provide a suitable means of treatment of end-stage renal failure complicating systemic amyloidosis both in terms of control of uraemia and quality of life, and that it provides the treatment of choice in selected patients.
